雄激素在前列腺癌中的作用。
Androgen action in prostate cancer.
机构信息
Department of Pathology, Ohio State University, Columbus, OH 43210, USA.
出版信息
Horm Cancer. 2010 Oct;1(5):223-8. doi: 10.1007/s12672-010-0044-4.
Abstract
Prostate cancer represents a major health problem in men worldwide. Androgens are required for the growth and maintenance of the prostate. Androgens act by binding to the androgen receptor (AR), a nuclear receptor transcription factor present in the prostate tissues. Most prostate tumors also retain their androgen dependence; therefore, androgen ablation is usually the preferred initial therapeutic approach for the treatment of advanced prostate cancer patients. This review summarizes the current information regarding the role of androgens in prostate cancer.
摘要
前列腺癌是全球男性面临的主要健康问题。雄激素对于前列腺的生长和维持是必需的。雄激素通过与雄激素受体（AR）结合而发挥作用，AR 是一种存在于前列腺组织中的核受体转录因子。大多数前列腺肿瘤仍然依赖雄激素；因此，雄激素剥夺通常是治疗晚期前列腺癌患者的首选初始治疗方法。本文综述了雄激素在前列腺癌中的作用的最新信息。
相似文献
1
Androgen action in prostate cancer.雄激素在前列腺癌中的作用。
Horm Cancer. 2010 Oct;1(5):223-8. doi: 10.1007/s12672-010-0044-4.
2
Androgen signaling and its interactions with other signaling pathways in prostate cancer.雄激素信号传导及其在前列腺癌中与其他信号通路的相互作用。
Bioessays. 2007 Dec;29(12):1227-38. doi: 10.1002/bies.20676.
3
Androgen action in the prostate gland.雄激素在前列腺中的作用。
Minerva Urol Nefrol. 2012 Mar;64(1):35-49.
4
Molecular regulation of androgen action in prostate cancer.前列腺癌中雄激素作用的分子调控
J Cell Biochem. 2006 Oct 1;99(2):333-44. doi: 10.1002/jcb.20794.
5
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.转移性前列腺癌中瘤内雄激素的维持：去势抵抗性肿瘤生长的一种机制。
Cancer Res. 2008 Jun 1;68(11):4447-54. doi: 10.1158/0008-5472.CAN-08-0249.
6
Androgens and androgen receptor signaling in prostate tumorigenesis.雄激素及雄激素受体信号传导在前列腺肿瘤发生中的作用
J Mol Endocrinol. 2015 Feb;54(1):R15-29. doi: 10.1530/JME-14-0203. Epub 2014 Oct 28.
7
The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.雄激素受体在前列腺增生和前列腺癌发生发展中的作用。
Mol Cell Biochem. 2003 Nov;253(1-2):89-101. doi: 10.1023/a:1026057402945.
8
Androgen receptor action in hormone-dependent and recurrent prostate cancer.雄激素受体在激素依赖性和复发性前列腺癌中的作用。
J Cell Biochem. 2006 Oct 1;99(2):362-72. doi: 10.1002/jcb.20811.
9
Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol.雄激素非依赖性前列腺癌细胞具备从胆固醇合成睾酮的完整类固醇生成能力。
Mol Cell Endocrinol. 2008 Nov 25;295(1-2):115-20. doi: 10.1016/j.mce.2008.08.013. Epub 2008 Aug 20.
10
Androgen receptor signaling in androgen-refractory prostate cancer.雄激素难治性前列腺癌中的雄激素受体信号传导
J Natl Cancer Inst. 2001 Nov 21;93(22):1687-97. doi: 10.1093/jnci/93.22.1687.
引用本文的文献
1
Red deer (Cervus elaphus L.) antler stem cell culture medium inhibits prostate cancer cells.马鹿（Cervus elaphus L.）鹿茸干细胞培养基可抑制前列腺癌细胞。
Histochem Cell Biol. 2025 Apr 2;163(1):41. doi: 10.1007/s00418-025-02373-6.
2
Reduction of Prostate Cancer Risk: Role of Frequent Ejaculation-Associated Mechanisms.降低前列腺癌风险：频繁射精相关机制的作用
Cancers (Basel). 2025 Feb 28;17(5):843. doi: 10.3390/cancers17050843.
3
Steroidogenic cytochrome P450 enzymes as drug target.作为药物靶点的类固醇生成细胞色素P450酶。
Toxicol Res. 2024 Apr 22;40(3):325-333. doi: 10.1007/s43188-024-00237-0. eCollection 2024 Jul.
4
Resistin stimulates PC-3 prostate cancer cell growth through stimulation of SOCS3 and SOCS5 genes.抵抗素通过刺激 SOCS3 和 SOCS5 基因刺激 PC-3 前列腺癌细胞生长。
Exp Biol Med (Maywood). 2023 Oct;248(20):1695-1707. doi: 10.1177/15353702231191206. Epub 2023 Aug 30.
5
Novel Functionalized Spiro [Indoline-3,5'-pyrroline]-2,2'dione Derivatives: Synthesis, Characterization, Drug-Likeness, ADME, and Anticancer Potential.新型功能化螺[吲哚啉-3,5'-吡咯啉]-2,2'-二酮衍生物：合成、表征、类药性、ADME 及抗癌潜力。
Int J Mol Sci. 2023 Apr 15;24(8):7336. doi: 10.3390/ijms24087336.
6
Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression.对良性和恶性前列腺中的雄激素受体进行逐个细胞的定量分析，有助于更好地理解与癌症发生和进展相关的变化。
J Pathol Clin Res. 2023 Jul;9(4):285-301. doi: 10.1002/cjp2.319. Epub 2023 Apr 18.
7
Neuroprotective and anticancer effects of 7‑Methoxyheptaphylline via the TAK1 pathway.7-甲氧基海罂粟碱通过 TAK1 通路的神经保护和抗癌作用。
Oncol Rep. 2023 Jan;49(1). doi: 10.3892/or.2022.8452. Epub 2022 Nov 23.
8
WWOX and metabolic regulation in normal and pathological conditions.WWOX 与正常和病理条件下的代谢调节。
J Mol Med (Berl). 2022 Dec;100(12):1691-1702. doi: 10.1007/s00109-022-02265-5. Epub 2022 Oct 22.
9
Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones.前列腺原位肿瘤的时空分析表明存在治疗抵抗性克隆的预先存在。
Nat Commun. 2022 Sep 17;13(1):5475. doi: 10.1038/s41467-022-33069-3.
10
Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes.辛伐他汀和三氧化二砷通过下调 VEGF 和 OPN 异构体基因对前列腺癌细胞系的联合抗癌作用。
J Cell Mol Med. 2022 May;26(9):2728-2740. doi: 10.1111/jcmm.17286. Epub 2022 Apr 2.
本文引用的文献
1
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.在人类前列腺癌中，雄激素受体剪接变体的频繁发生导致去势抵抗。
J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.
2
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.雄激素受体氨基端结构域小分子抑制剂抑制去势复发前列腺癌
Cancer Cell. 2010 Jun 15;17(6):535-46. doi: 10.1016/j.ccr.2010.04.027.
3
New developments in the medical management of prostate cancer.前列腺癌的医学管理新进展。
Mayo Clin Proc. 2010 Jan;85(1):77-86. doi: 10.4065/mcp.2009.0442.
4
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.血清睾酮与老年男性侵袭性前列腺癌相关：巴尔的摩纵向衰老研究的结果。
BJU Int. 2010 Mar;105(6):824-9. doi: 10.1111/j.1464-410X.2009.08853.x. Epub 2009 Sep 14.
5
Castration-resistant prostate cancer: locking up the molecular escape routes.去势抵抗性前列腺癌：阻断分子逃逸途径
Clin Cancer Res. 2009 May 15;15(10):3251-5. doi: 10.1158/1078-0432.CCR-08-1171.
6
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.前列腺癌中与治疗相关的雄激素受体突变利用多种机制逃避治疗。
Cancer Res. 2009 May 15;69(10):4434-42. doi: 10.1158/0008-5472.CAN-08-3605. Epub 2009 Apr 14.
7
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.一种新型雄激素受体剪接变体在前列腺癌进展过程中上调，并促进抗雄激素耗竭的生长。
Cancer Res. 2009 Mar 15;69(6):2305-13. doi: 10.1158/0008-5472.CAN-08-3795. Epub 2009 Feb 24.
8
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.源自隐蔽外显子剪接的非配体依赖性雄激素受体变体意味着激素难治性前列腺癌。
Cancer Res. 2009 Jan 1;69(1):16-22. doi: 10.1158/0008-5472.CAN-08-2764.
9
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.一种新型雄激素受体外显子的剪接产生一种组成型活性雄激素受体，介导前列腺癌治疗耐药性。
Cancer Res. 2008 Jul 1;68(13):5469-77. doi: 10.1158/0008-5472.CAN-08-0594.
10
Cancer statistics, 2008.2008年癌症统计数据。
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.
Zotero 插件